Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker M&A Strategy Intact Under New CEO With Latest Deal For Stroke Care

This article was originally published in The Gray Sheet

Executive Summary

Purchase of Surpass Medical for $135 million represents Stryker’s 10th acquisition since 2009. The company affirmed its acquisition strategy focused on core and key adjacent markets during its Oct. 17 earnings call, but also sought to ratchet down earnings growth expectations in the near term to account for headwinds, including the upcoming U.S. medical device excise tax.

You may also be interested in...



Global Device Approvals, Weekly Snapshot: July 9-15, 2018

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. This week, Stryker gets a go-ahead to enter the US flow diverter/aneurysm market, and nine CE marks are highlighted.

Device/Diagnostics Quarterly Deal Statistics, Q4 2012

Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.

Market & Industry Briefs, November 2012

Brief summaries of recent medtech market and industry developments. This month we cover China’s switch to a centralized billing system, St. Jude Medical’s RESPECT PFO closure trial, FDA’s approval of HeartWare’s LVAD, and end-of-the-year medtech M&A.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel